Emyria Ltd has released a press release.
September 2023 Quarterly Activities Report and Appendix 4C
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from Emyria
- Health Canada Approval Received for MDMA Import
- Emyria's Clinic Achieves Key MDMA-AT Dosing Milestone
- Completion of Entitlement Offer
- Emyria set to begin MDMA study after securing local supply
- Emyria Secures Local MDMA to Start PTSD Trial Dosing
Later from Emyria
- Emyria hails strong growth in clinical billings
- Emyria Secures Ethics Endorsement for MDMA AP Application
- Board Changes and Executive Restructuring
- Emyria Specialist Granted Authorised Prescriber Status
- Emyria Receives $2.5M R&D Tax Incentive Refund
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria